Institutional shares held 135 Million
426K calls
119K puts
Total value of holdings $1.56B
$4.9M calls
$1.37M puts
Market Cap $889M
76,966,896 Shares Out.
Institutional ownership 175.49%
# of Institutions 206


Latest Institutional Activity in OCUL

Top Purchases

Q2 2025
Imc Chicago, LLC Shares Held: 208K ($2.4M)
Q2 2025
Deltec Asset Management LLC Shares Held: 2.79M ($32.3M)
Q2 2025
Truist Financial Corp Shares Held: 100K ($1.16M)
Q2 2025
Simplicity Wealth,Llc Shares Held: 40.3K ($466K)
Q2 2025
Klp Kapitalforvaltning As Shares Held: 23.7K ($274K)

Top Sells

Q2 2025
Assenagon Asset Management S.A. Shares Held: 194K ($2.24M)
Q2 2025
Farther Finance Advisors, LLC Shares Held: 281 ($3.25K)
Q1 2025
Opaleye Management Inc. Shares Held: 1.6M ($18.4M)
Q1 2025
Logos Global Management LP Shares Held: 2.3M ($26.6M)
Q1 2025
Point72 Asset Management, L.P. Shares Held: 1.94M ($22.4M)

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.


Insider Transactions at OCUL

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
3.53M Shares
From 14 Insiders
Grant, award, or other acquisition 3.52M shares
Open market or private purchase 10K shares
Sell / Disposition
141K Shares
From 6 Insiders
Open market or private sale 141K shares

Track Institutional and Insider Activities on OCUL

Follow OCULAR THERAPEUTIX, INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells OCUL shares.

Notify only if

Insider Trading

Get notified when an Ocular Therapeutix, Inc insider buys or sells OCUL shares.

Notify only if

News

Receive news related to OCULAR THERAPEUTIX, INC

Track Activities on OCUL